Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$928.00K$928.00K+32.4% vs Q1 2018 Net Income$39.31M$39.31MN/M vs Q1 2018 EPS Diluted$0.30$0.30N/M vs Q1 2018 Gross Profit$860,000+45.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flow-$9,314,000N/M Free Cash Flowderived-$9,483,000N/M Margins · derivedGross margin92.7%+8.2 pt vs Q1 2018
Operating margin-1375.1%+363.4 pt vs Q1 2018
Net margin4236.0%+13301.3 pt vs Q1 2018
ended Mar 31, 2019 · filed May 9, 2019 · 39 d after period end